Azetukalner

DRUG5 trials

Sponsors

Xenon Pharmaceuticals Inc.

Conditions

Bipolar DepressionBipolar DisorderBipolar I DisorderBipolar II DisorderMajor Depressive Disorder

Phase 3

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

RecruitingNCT06775379

Xenon Pharmaceuticals Inc.Major Depressive Disorder

Start: 2024-12-20End: 2026-10-01Target: 450Updated: 2026-08-03

An Open-Label Study of Azetukalner in Major Depressive Disorder

Enrolling by invitationNCT06922110

Xenon Pharmaceuticals Inc.Major Depressive Disorder

Start: 2025-03-18End: 2027-03-01Target: 460Updated: 2026-09-03

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

RecruitingNCT07076407

Xenon Pharmaceuticals Inc.Major Depressive Disorder

Start: 2025-07-08End: 2027-07-01Target: 450Updated: 2026-09-08

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

RecruitingNCT07172516

Xenon Pharmaceuticals Inc.Bipolar Depression, Bipolar Disorder, Bipolar I Disorder +1

Start: 2025-08-08End: 2028-08-01Target: 400Updated: 2026-09-02

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

Enrolling by invitationNCT07217860

Xenon Pharmaceuticals Inc.Bipolar Depression, Bipolar Disorder, Bipolar I Disorder +1

Start: 2025-10-30End: 2029-08-01Target: 400Updated: 2026-09-02